Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4713352A · kind A · utility
25Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 1984 |
| Grant date | Dec 15, 1987 |
| Priority date | — |
| Expiry date | May 4, 2004 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/864
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A panel of monoclonal antibodies is developed for use in diagnosis and treatment of renal carcinoma. One monoclonal antibody F.sub.31 reacts with 80% of renal carcinoma. The area of overlap of reactivity of monoclonal antibodies F.sub.31, F.sub.23, S.sub.4, S.sub.23 and S.sub.27 is the site of origin of most renal carcinomas. Reactivity with this panel of monoclonal antibodies localizes most renal carcinoma and is a vehicle for early diagnosis and treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.